The preventable burden of pneumococcal disease in the developing world
Clicks: 356
ID: 111098
2007
Article Quality & Performance Metrics
Overall Quality
Improving Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
Emerging Content
8.7
/100
29 views
29 readers
Trending
AI Quality Assessment
Not analyzed
Abstract
The efficacy of pneumococcal conjugate vaccines (PCV) and their remarkable success in operational use in North America challenge us to define the burden of pneumococcal disease and the likely benefits of PCV use in developing countries. Community-based incidence studies of invasive pneumococcal dise …
| Reference Key |
ja2007vaccinethe
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Scott JA;; |
| Journal | Vaccine |
| Year | 2007 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
National Center for Biotechnology Information
NCBI
NLM
MEDLINE
review
humans
pubmed abstract
nih
national institutes of health
national library of medicine
research support
non-u.s. gov't
Child
Infant
newborn
preschool
vaccines
pmid:17028081
doi:10.1016/j.vaccine.2006.09.008
j a g scott
developing countries
pneumococcal infections / epidemiology*
pneumococcal infections / mortality
pneumococcal infections / prevention & control*
pneumococcal vaccines / immunology
pneumococcal vaccines / therapeutic use*
conjugate / immunology
conjugate / therapeutic use
|
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.